Critical Analysis: Accenture (NYSE:ACN) & Medical Cannabis Payment Solutions (OTCMKTS:REFG)

Medical Cannabis Payment Solutions (OTCMKTS:REFG) and Accenture (NYSE:ACN) are both business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Insider and Institutional Ownership

75.1% of Accenture shares are owned by institutional investors. 0.0% of Accenture shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Medical Cannabis Payment Solutions and Accenture”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medical Cannabis Payment Solutions	$140,000.00	0.43	-$30,000.00	N/A	N/A
Accenture	$66.36 billion	3.41	$7.26 billion	$11.92	30.34

Accenture has higher revenue and earnings than Medical Cannabis Payment Solutions.

Profitability

This table compares Medical Cannabis Payment Solutions and Accenture’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medical Cannabis Payment Solutions	N/A	N/A	N/A
Accenture	11.20%	26.83%	14.27%

Analyst Recommendations

This is a breakdown of current ratings for Medical Cannabis Payment Solutions and Accenture, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medical Cannabis Payment Solutions	0	0	0	0	0.00
Accenture	0	8	14	0	2.64

Accenture has a consensus target price of $383.23, indicating a potential upside of 5.97%. Given Accenture’s stronger consensus rating and higher possible upside, analysts plainly believe Accenture is more favorable than Medical Cannabis Payment Solutions.

Risk and Volatility

Medical Cannabis Payment Solutions has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Accenture has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Summary

Accenture beats Medical Cannabis Payment Solutions on 12 of the 12 factors compared between the two stocks.

About Medical Cannabis Payment Solutions

Medical Cannabis Payment Solutions, Inc. develops and markets a payment system for medical cannabis transactions. Its solution assists in the state tracking of sales, collection of tax, and supervision of sales to consumers. The company was incorporated in 2013 and is based in Cheyenne, Wyoming. On August 12, 2024, Medical Cannabis Payment Solutions, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.

About Accenture

Accenture plc, a professional services company, provides strategy and consulting, industry X, song, and technology and operation services worldwide. The company offers application services, including agile transformation, DevOps, application modernization, enterprise architecture, software and quality engineering, data management; intelligent automation comprising robotic process automation, natural language processing, and virtual agents; and application management services, as well as software engineering services; strategy and consulting services; data and analytics strategy, data discovery and augmentation, data management and beyond, data democratization, and industrialized solutions comprising turnkey analytics and artificial intelligence (AI) solutions; metaverse; and sustainability services. It also provides change management, HR transformation and delivery, organization strategy and design, talent strategy and development, and leadership and culture services; digital commerce; infrastructure services, including cloud infrastructure managed, cloud and data center, network, digital workplace, database platforms, service management, and cloud and infrastructure security services; data-enabled operating models; technology consulting and AI services; and technology consulting services. In addition, the company offers engineering and R&D digitization, smart connected products, product as-a-service enablement, capital projects, intelligent asset management, digital industrial workforce, and autonomous robotic systems; business process outsourcing; and services related to technology innovation. Further, it provides cloud, ecosystem, marketing, security, supply chain management, zero-based transformation, customer experience, finance consulting, mergers and acquisitions, and sustainability services. The company has a collaboration with Salesforce, Inc. to develop Salesforce Life Sciences Cloud. The company was founded in 1951 and is based in Dublin, Ireland.